A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications

T. E. F. Abbott\textsuperscript{1,2}, A. J. Fowler\textsuperscript{1}, P. Pelosi\textsuperscript{3}, M. Gama de Abreu\textsuperscript{4}, A. M. Møller\textsuperscript{5}, J. Canet\textsuperscript{6}, B. Creagh-Brown\textsuperscript{7,8}, M. Mythen\textsuperscript{2}, T. Gin\textsuperscript{9}, M. M. Lalu\textsuperscript{10}, E. Futier\textsuperscript{11}, M. P. Grocott\textsuperscript{12,13}, M. J. Schultz\textsuperscript{14,15}, R. M. Pearse\textsuperscript{1,*}, and the StEP-COMPAC Group\textsuperscript{#}

\textsuperscript{1}Queen Mary University of London, London, UK, \textsuperscript{2}Department of Anaesthesia and Critical Care, University College London Hospital, London, UK, \textsuperscript{3}Department of Surgical Sciences and Integrated Diagnostics, San Martino Policlinico Hospital, IRCCS for Oncology, University of Genoa, Genoa, Italy, \textsuperscript{4}Department of Anesthesiology and Intensive Care Therapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, \textsuperscript{5}Department of Anaesthesiology and Intensive Care Medicine, Herlev University Hospital, Herlev, Denmark, \textsuperscript{6}Department of Anaesthesiology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, \textsuperscript{7}Intensive Care Unit, Royal Surrey County Hospital, Guildford, UK, \textsuperscript{8}Surrey Perioperative Anaesthesia Critical Care Collaborative Research Group (SPACeR), Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK, \textsuperscript{9}Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China, \textsuperscript{10}Department of Anesthesiology and Pain Medicine, Ottawa Hospital, University of Ottawa, Clinical Epidemiology and Regenerative Medicine Programs, Ottawa Hospital Research Institute, Ottawa, ON, Canada, \textsuperscript{11}Department of Perioperative Medicine, Anaesthesiology and Critical Care, Estaing Hospital, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France, \textsuperscript{12}Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK, \textsuperscript{13}Critical Care Research Group, Southampton NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK, \textsuperscript{14}Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands and \textsuperscript{15}Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand

*Corresponding author. E-mail: r.pearse@qmul.ac.uk

Abstract

Background: There is a need for robust, clearly defined, patient-relevant outcome measures for use in randomised trials in perioperative medicine. Our objective was to establish standard outcome measures for postoperative pulmonary complications research.

Methods: A systematic literature search was conducted using MEDLINE, Web of Science, SciELO, and the Korean Journal Database. Definitions were extracted from included manuscripts. We then conducted a three-stage Delphi consensus process to select the optimal outcome measures in terms of methodological quality and overall suitability for perioperative trials.

Results: From 2358 records, the full texts of 81 manuscripts were retrieved, of which 45 met the inclusion criteria. We identified three main categories of outcome measure specific to perioperative pulmonary outcomes: (i) composite outcome measures of multiple pulmonary outcomes (27 definitions); (ii) pneumonia (12 definitions); and (iii) respiratory failure (six definitions). These were rated by the group according to suitability for routine use. The majority of definitions were given a low score, and many were imprecise, difficult to apply consistently, or both, in large patient populations. A small number of highly rated definitions were identified as appropriate for widespread use. The group then recommended four outcome measures for future use, including one new definition.

Conclusions: A large number of postoperative pulmonary outcome measures have been used, but most are poorly defined. Our four recommended outcome measures include a new definition of postoperative pulmonary complications, incorporating an assessment of severity. These definitions will meet the needs of most clinical effectiveness trials of treatments to improve postoperative pulmonary outcomes.

Keywords: outcome assessment (healthcare)/standards; perioperative care/methods

Each year, more than 300 million patients undergo surgery worldwide. Estimates of attributable mortality vary from 1% to 4%, however some studies suggest that more than one in five deaths occur in a small group of high-risk patients. Even when complications are successfully treated, these are still associated with reduced long-term survival. Some of the most common postoperative complications affect the respiratory tract, with incidences ranging from 9% to 40%, depending on the definition used. A number of factors promote pulmonary complications amongst patients undergoing major surgery. Anaesthesia can lead to reduced functional residual capacity, hypoxaemia, and impaired central respiratory drive, while surgical manipulation can restrict ventilation, damage respiratory muscles, and cause atelectasis. When combined with pre-existing respiratory disease and postoperative pain, the risk of pneumonia, respiratory failure, and death is increased. There is a need for large, high quality clinical trials to improve the treatment of patients at risk of postoperative pulmonary complications.

The impact of any large clinical trial is critically dependent on the use of well-defined outcome measures, which must be patient-centred, reliable, valid, and potentially modifiable by the trial intervention. Inconsistent reporting of outcomes across trials investigating similar clinical problems hinders the interpretation of new research findings in the context of existing research evidence, and prevents the use of pooled data in systematic reviews. Many definitions are similar but not sufficiently so to allow robust comparison. There is a recognised need for a standardised list of clearly defined clinical outcome measures for use in large, pragmatic clinical trials in this field. This would help investigators to improve the design of clinical trials through the use of recognised reference standards. This should lead to a stronger evidence base to inform clinical practice and improve short- and long-term outcomes for patients after surgery.

The Standardized Endpoints for Perioperative Medicine (StEP) collaboration was established to evaluate the literature and create standards for the definition and use of outcome measures in clinical effectiveness research in perioperative medicine, addressing the need for greater precision and consistency in defining outcomes for perioperative clinical trials. As part of this initiative, we performed a systematic literature review of clinical trials and observational studies of pulmonary outcomes in perioperative care, followed by a Delphi process to develop recommendations for standardised outcomes.

Methods

Members of the group were recruited to better understand and improve the pulmonary morbidity, which occurs during and after surgery. We performed a systematic literature review to identify studies with relevant clinical outcome measures that should be considered for future use in clinical trials. The group then evaluated these outcomes to decide which should be considered as evidence in a wider evaluation of clinical outcome measures in all areas of perioperative medicine.

Search strategy

Stage 1: literature search to develop preliminary list of trial endpoints and definitions

Publications identified in the literature search were used to create a preliminary list of outcome measures and their definitions.

Stage 2: formal rating of the recommendations (Delphi round one)

We extracted the outcome measures from manuscripts identified in our literature search, and then created summary tables in different categories, allowing easy comparison of outcome measure definitions. We circulated these tables within the Pulmonary StEP theme group and asked members to submit their ratings via an online form. Manuscripts were first evaluated by using a ‘traffic light’ scale (green/amber/red) for methodological quality, and overall suitability as endpoints in the context of perioperative trials. This rating encompassed validity, reliability, ease of use, and frequency of use in the perioperative literature. Where two or more alternative definitions were very similar, we promoted use of the more precise and detailed alternative(s). Definitions that had been superseded or were clearly out of date were categorised as red.

Stage 3: Delphi round two

The second Delphi round included participants from the entire StEP Working Group (n=75). Participants were asked to score each of the items listed using a scale of 1–9, with 1–3 labelled ‘Not that important or invalid’, 4–6 labelled ‘Important but requires revision’, and 7–9 labelled ‘Critical for inclusion’. Participants were given the option to select ‘unsure’ if they were unable to offer an opinion as to which category to apply to the item. Participants were invited to suggest any other endpoints, or definitions, or modifications to existing definitions that they believed should be included. A reminder email was sent to ensure prompt completion of the survey. The final numbers of respondents and item completions were recorded. The number of participants who scored the item and the median, and inter-quartile range of scores were quantified. Members of the Pulmonary StEP theme group were then invited to discuss the results via email. Any items not rated as critical (i.e. 70th centile score <7) but still with a median score of 7 or greater were retained for consideration in the second round. Lower-rated endpoint items identified for removal could be retained if they were considered as critical by any group member for the second round. Items with a median score of ≤3 were not retained.

Stage 4: Delphi round three and final recommendations

Delphi round three included members of the Pulmonary StEP theme group (n=14). The summary results of the above process were provided to these participants, inviting further comments. If responses to this final stage suggested a need for further modification to endpoint definitions, then this was resolved by the authors via email discussion.

Results

Study selection

We identified 2366 records from the electronic search strategy, and a further 13 records through other sources. After removal...
<table>
<thead>
<tr>
<th>Lead author</th>
<th>Outcome measure</th>
<th>Definition</th>
<th>Round 1</th>
<th>Round 2</th>
<th>Round 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agostini and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Four or more of: atelectasis or consolidation on chest X-ray; white cell count $&gt;11.2 \times 10^9$ litre$^{-1}$ or administration of respiratory antibiotics after operation (in addition to prophylactic antibiotics); temperature $&gt;38^\circ C$; signs of infection on sputum microbiology; purulent sputum differing from preoperative status; oxygen saturations $&lt;90%$ on room air; physician diagnosis of pneumonia; or prolonged high dependency unit (HDU) stay or readmission to HDU or intensive care unit (ICU) for respiratory complications.</td>
<td>Red</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Barrera and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Any of: respiratory failure requiring intensive care admission, intubation, or both; pneumonia (new pulmonary infiltrate with fever treated with i.v. antibiotics); atelectasis requiring bronchoscopy (need determined by the surgical team); pulmonary embolism (diagnosed by computed tomography scan and treated); and need for supplemental oxygen at hospital discharge.</td>
<td>Red</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Bellinetti and colleagues</td>
<td>Postoperative respiratory complications</td>
<td>Any of: pneumonia (core temperature more than $38^\circ C$, radiological signs of pulmonary consolidation, and productive cough); atelectasis with evident clinical repercussions; bronchospasm; prolonged mechanical ventilation; pleural effusion or pneumothorax; surgical re-intervention caused by inadequate lung re-expansion; or death related or not to pulmonary disease.</td>
<td>Amber</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Canet and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Any of: respiratory infection (antibiotics for a suspected respiratory infection and at least one of: new or changed sputum, new or changed lung opacities, fever, leucocyte count $&gt;12 000$ $\mu l^{-1}$), respiratory failure (postoperative $\text{PaO}_2 &lt; 60$ mm Hg on room air, a ratio of $\text{PaO}_2$ to inspired oxygen fraction $&lt;300$, or pulse oximetry $&lt;90%$ and requiring oxygen therapy), pleural effusion (chest X-ray demonstrating blunting of the costo-phrenic angle, loss of the sharp silhouette of the ipsilateral hemi-diaphragm when upright, displacement of adjacent anatomical structures, or a hazy opacity in one hemithorax with preserved vascular shadows when supine), atelectasis (lung opacification with a shift of the mediastinum, hilum or hemi-diaphragm, and compensatory over inflation in the adjacent non-atelectatic lung), pneumothorax (air in the pleural space with no vascular bed surrounding the visceral pleura), bronchospasm (newly detected expiratory wheezing), or aspiration pneumonitis (acute lung injury after the inhalation of regurgitated gastric contents).</td>
<td>Green</td>
<td>Median score 7 44/75 scored $\geq$7</td>
<td>Median score 7 6/10 scored $\geq$7</td>
</tr>
<tr>
<td>Casado and colleagues</td>
<td>Respiratory complications</td>
<td>Any of: pneumonia confirmed by a positive culture result (tracheal aspiration or blood sample) or chest X-ray; acute lung injury ($\text{PaO}_2/\text{FiO}_2 &lt; 300$), or adult distress respiratory syndrome (ARDS) ($\text{PaO}_2/\text{FiO}_2 &lt; 200$ regardless of the level of PEEP, pulmonary capillary wedge pressure $&lt;18$ mm Hg or bilateral infiltrates consistent with pulmonary oedema without clinical evidence of left ventricular failure) according to the American–European Consensus Conference (1994).</td>
<td>Red</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Dronkers and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Operationalised as atelectasis, which is considered a ‘precursor’ of more clinically relevant postoperative pulmonary complications. A</td>
<td>Red</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Lead author</td>
<td>Outcome measure</td>
<td>Definition</td>
<td>Round 1</td>
<td>Round 2</td>
<td>Round 3</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Futier and colleagues</td>
<td>Major pulmonary complications</td>
<td>blinded radiologist evaluated radiographs of the lung base for the presence of atelectasis. Pneumonia defined according to standard criteria or the need for invasive or non-invasive ventilation for acute respiratory failure.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Galvao Serejo and</td>
<td>Postoperative pulmonary complications</td>
<td>Any of: pneumonia (presence of new or progressive pulmonary infiltration on chest X-ray associated with at least two of: purulent trachea-bronchial secretion, elevated temperature &gt;38.3°C, or increased blood leucocytes (&gt;25% of base count); atelectasis (pulmonary atelectasis on chest X-ray associated with acute respiratory symptoms without fulfilling the criteria for pneumonia); pleural effusion (excessive fluid in the pleural space, detected by clinical examination and chest radiograph, requiring percutaneous intervention); acute respiratory failure (acute deficiency of gas exchange requiring mechanical ventilation). If patients with pneumonia developed respiratory failure they would be included only in the group ‘acute respiratory failure’.</td>
<td>Amber</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Grant and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Any of: acute lung injury, pulmonary infection, or atelectasis, as defined by the individual studies included in the meta-analysis.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Guimaraes and colleagues</td>
<td>Pulmonary complications</td>
<td>Any of: (i) atelectasis (radiographic, tomographic, or bronchoscopic diagnosis in patients whose clinical signs were acute respiratory symptoms such as dyspnoea, cough, wheeze); (ii) respiratory failure (radiographical diagnosis in patients with signs of acute respiratory symptoms such as tracheobronchial purulent secretions, fever (&gt;38°C), or increased white blood cell (WBC) count (&gt;10 000 mm⁻³); or (iii) tracheobronchial infection or pneumonia.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Haines and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Four or more of: chest radiograph report of collapse/consolidation; oral temperature &gt;38°C on more than one consecutive postoperative day; pulse-oximetry (SpO₂) &lt;90% on more than one consecutive postoperative day; production of yellow or green sputum different to preoperative assessment; infection on sputum culture report; unexplained white cell count &gt;11·10⁹ litre⁻¹ or antibiotic therapy for respiratory infection; new abnormal breath sounds on auscultation different to preoperative assessment; or physician diagnosis of postoperative pulmonary complication.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Hemmes and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Any of: hypoxaemia, severe hypoxaemia, bronchospasm, suspected pulmonary infection, pulmonary infiltrate, aspiration pneumonia, development of Acute Respiratory Distress Syndrome, atelectasis, pleural effusion, pulmonary oedema caused by cardiac failure, and pneumothorax.</td>
<td>Green</td>
<td>Median score 6 32/75 scored ≥7</td>
<td>Median score 6 5/10 scored ≥7</td>
</tr>
<tr>
<td>Hodari and colleagues</td>
<td>Postoperative respiratory outcomes</td>
<td>Respiratory outcomes tracked in National Surgical Quality Improvement Program (NSQIP): reintubation (placement of an tracheal tube and mechanical or assisted ventilation because of respiratory or cardiac failure manifested by severe respiratory distress, hypoxia, hypercarbia, or respiratory acidosis within 30 days of surgery); postoperative pneumonia [one of two criteria: Criterion 1: rales or dullness to percussion on physical examination of chest plus: (i) new onset of purulent sputum or change in character of sputum; (ii) organism isolated from blood culture; or (iii) isolation of pathogen from specimen obtained by trans-tracheal aspirate, bronchial brushing, or biopsy. Criterion</td>
<td>Green</td>
<td>Median score 7 38/75 scored ≥7</td>
<td>Median score 6 4/10 scored ≥7</td>
</tr>
</tbody>
</table>
Table 1 Continued

<table>
<thead>
<tr>
<th>Lead author</th>
<th>Outcome measure</th>
<th>Definition</th>
<th>Round 1</th>
<th>Round 2</th>
<th>Round 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hulzebos and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>2: chest X-ray shows new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of: (i) new onset of purulent sputum or change in character of sputum; (ii) organism isolated from blood culture; (iii) isolation of pathogen from specimen obtained by trans-tracheal aspirate, bronchial brushing, or biopsy; (iv) isolation of virus or detection of viral antigen in respiratory secretions; (v) diagnostic single antibody titre (immunoglobulin M) or four-fold increase in paired serum samples (immunoglobulin G) for pathogen; or (vi) histopathologic evidence of pneumonia; and prolonged ventilation (ventilator-assisted respirations during postoperative hospitalisation &gt;48 h).</td>
<td>Green</td>
<td>Median score 7</td>
<td>Median score 6</td>
</tr>
<tr>
<td>Ireland and colleagues</td>
<td>Major respiratory complications</td>
<td>Significant atelectasis, pneumonia, significant hypoxia, tracheal re-intubation, ICU admission. Atelectasis was defined by the authors of the individual studies.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ladha and colleagues</td>
<td>Postoperative respiratory complications</td>
<td>Any of: re-intubation, respiratory failure, pneumonia, and pulmonary oedema within 3 days of the procedure.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Li and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Pulmonary infection (fever with positive sputum culture and infiltration on chest X-ray), atelectasis, or hypoxemia (SaO₂ &lt;90% for &gt;30 min).</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Lunardi and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Any of: atelectasis with clinical consequences, hypoxia with oxygen saturation &lt;85% and need of supplemental oxygen, pneumonia, or acute respiratory failure.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Mackay and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Three or more of the following signs within the same day, in the first 14 days after surgery: Auscultation changes (decreased breath sounds, crackles, wheezes, bronchial breathing) that were additional to those found before surgery. Temperature &gt;38°C. Chest X-ray changes consistent with collapse, consolidation, or atelectasis. Increase in amount, changed colour, or both, of sputum produced, compared with what the patient reports is usual for them.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>McAlister and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Any one of: respiratory failure requiring mechanical ventilation, pneumonia, atelectasis requiring bronchoscopic intervention, and</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Lead author</th>
<th>Outcome measure</th>
<th>Definition</th>
<th>Round 1</th>
<th>Round 2</th>
<th>Round 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muehling and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Pneumothorax or pleural effusion requiring percutaneous intervention. Any one of: atelectasis; pneumonia; or prolonged air leak &gt; 7 days. Atelectasis was diagnosed on chest X-ray or computed tomography scan; pneumonia was confirmed if antibiotic medication was required because of clinical and radiological signs of infection combined with elevated white cell count or raised C-reactive protein (CRP).</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Nascimento and colleagues</td>
<td>Pulmonary complications</td>
<td>Any one of: atelectasis (radiographic, tomographic, or bronchoscopic diagnosis in patients whose clinical signs were acute respiratory symptoms such as dyspnoea, cough, wheeze); respiratory failure (radiographical diagnosis in patients with signs of acute respiratory symptoms such as tracheobronchial purulent secretions, fever (&gt;38°C), or increased WBC count (&gt;10 000 mm^3); tracheobronchial infection or pneumonia.</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Paisani and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>One or more of: pneumonia (presence of radiological evidence of pulmonary infiltration associated with at least two of: purulent sputum, temperature &gt; 38.0°C or leucocytosis &gt; 25% above baseline value); trachea-bronchitis (marked increase in sputum production or presence of purulent sputum when chest X-ray normal); atelectasis (radiological evidence of atelectasis associated with dyspnoea); acute respiratory failure (acute deficiency of gas exchange with necessity for invasive or non-invasive mechanical ventilation); bronchoconstriction (wheezing associated with dyspnoea, requiring bronchodilators or change in previous dosage of bronchodilator.</td>
<td>Amber</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Scholes and colleagues</td>
<td>Pulmonary complications</td>
<td>Four or more of: chest radiograph report of collapse/consolidation; oral temperature &gt;38°C on more than one consecutive postoperative day; pulse-oximetry (SpO_2) &lt;90% on more than one consecutive postoperative day; production of yellow or green sputum different to preoperative assessment; infection on sputum culture report; unexplained white cell count &gt;11 x 10^9 litre^-1 or antibiotic therapy for respiratory infection; new abnormal breath sounds on auscultation different to preoperative assessment; or physician diagnosis of postoperative pulmonary complication.</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Vidotto and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Any one of: acute respiratory infection (pneumonia or purulent trachea-bronchitis, where pneumonia was established by the presence of lung infiltration on chest X-ray associated with at least two of: purulent tracheobronchial secretion, temperature &gt;38.3°C or a 25% increase in baseline blood leucocytes; and purulent trachea-bronchitis was diagnosed when tracheobronchial secretions increased in amount or changed in colour or purulence, associated with a normal chest X-ray; atelectasis (acute respiratory symptoms associated with radiological imaging); bronchospasm (wheezing detectable with a stethoscope associated with acute respiratory symptoms and the need for medication therapy).</td>
<td>Amber</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Yang and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>PaO_2/FIO_2 &gt;300 mm Hg, the presence of newly developed lung lesions (lung infiltration and atelectasis), or both, within 72 h of the operation.</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Zarbock and colleagues</td>
<td>Postoperative pulmonary complications</td>
<td>Any one of: decreased pulmonary oxygen transfer ratio, nosocomial pneumonia, re-intubation rate, and readmission to the ICU after elective discharge to the general ward.</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>
Table 2 Definitions of pneumonia outcome measures

<table>
<thead>
<tr>
<th>Lead author</th>
<th>Outcome measure</th>
<th>Definition</th>
<th>Round 1</th>
<th>Round 2</th>
<th>Round 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akutsu and colleagues</td>
<td>Postoperative pneumonia</td>
<td>All of: increase of sputum, opacity on chest X-ray, consolidation on computed tomography, increased temperature, increased WBC count, and CRP value in the serum.</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Cassidy and colleagues</td>
<td>Postoperative pneumonia</td>
<td>At least one definitive chest X-ray, and at least one sign (fever, leucocytosis, or altered mental status with no other cause), and at least one microbiologic laboratory finding (positive cultures from blood, broncho-alveolar lavage, or pleural fluid) or at least two symptoms (purulent sputum, worsening cough, dyspnoea or tachypnoea, rales or rhonchi, or worsening gas exchange).</td>
<td>Amber</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td>Markar and colleagues</td>
<td>Postoperative pneumonia</td>
<td>Pyrexia, productive cough, raised white cell count, and localising signs on chest examination or chest radiography.</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Schussler and colleagues (2006)</td>
<td>Postoperative pneumonia</td>
<td>Fibreoptic bronchoscopy samples were obtained before antibiotic therapy in every patient with signs of pneumonia: abnormal radiographic findings (new or changing radiographic infiltrates that persisted after physiotherapy or broncho-aspiration), fever &gt;38°C, and one of: a new increase in CRP or WBC count over the last 24 h (with WBC&gt;12×10^9 litre^-1) or increased and modified expectorate, possibly purulent. Patients with positive plugged telescopic catheter sample (&gt;10^3 colony-forming unit (CFU) ml^-1), protected specimen brush sample (&gt;10^3CFU ml^-1), or positive blood culture represented the 'documented POP' group. If the significant cut-off values were not reached, but clinical and radiologic improvement occurred after the administration of antibiotics, patients were considered as having 'non-documented POP.'</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Schussler and colleagues (2008)</td>
<td>Postoperative pneumonia</td>
<td>Quantitative fibreoptic bronchoscopy aspiration, plugged telescopic catheter (PTC), or protected specimen brush (PSB) sampling in case of: abnormal radiographic findings (new or changing radiographic infiltrates that persisted after physiotherapy or fibreoptic bronchial aspiration), fever &gt;38°C and one of: purulent secretions or an increase of &gt;30% of the CRP or WBC count during the last 24 h (with count &gt;12×10^9 litre^-1). Pneumonia was considered documented if bacteria were identified in blood culture or at the 48-h culture of the fibreoptic sample with thresholds: PTC or PSB at &gt;10^3 CFU ml^-1, or bilateral quantitative endobronchial aspirate (QEBA) at &gt;10^6 CFU ml^-1.</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Bagyi and colleagues</td>
<td>Pneumonia</td>
<td>According to American Thoracic Society guidelines by X-ray (new or progressive radiographic infiltrate), new onset of fever &gt;38.0°C, symptoms of coughing with purulent sputum, chest pain and leucocytosis (WBC &gt;10 g litre^-1).</td>
<td>Red</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Centers for Disease Control definition</td>
<td>Pneumonia</td>
<td>Two or more serial chest radiographs with at least one of the following (one radiograph is sufficient for patients with no underlying pulmonary or cardiac disease): (i) New or progressive and persistent infiltrates, (ii) consolidation, (iii) cavitation; at least one of the following: (a) fever (&gt;38°C) with no other recognised cause, (b) leucopenia (white cell count &lt;4×10^9 litre^-1) or leucocytosis (white cell count &gt;12×10^9 litre^-1), (c) for adults &gt;70 yr old, altered mental status with no other recognised cause; And at least two of the following:</td>
<td>Green</td>
<td>Median</td>
<td>Median</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>score 8</td>
<td>56/75</td>
<td>10/10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>scored ≥7</td>
<td>scored ≥7</td>
<td>scored ≥7</td>
</tr>
</tbody>
</table>
of duplicates, 2358 records remained. The full texts of 81 manuscripts were retrieved, of which 45 met the inclusion criteria (Supplementary Fig. S1 and Table S1). A summary of full texts excluded after review, with reason for exclusion, is shown in Supplementary Table S1. The definitions extracted from included studies are summarised in Table 1. We identified three main categories of outcome measure specific to pulmonary outcomes in perioperative medicine: (i) composite outcome measures including a number of pulmonary outcomes (27 definitions); (ii) pneumonia (12 definitions); and (iii) respiratory failure (six definitions). These are summarised in Supplementary Table S2, Tables 1–3, along with the rating (red/amber/green) given by the group and a summary definition of each outcome measure.

**Postoperative pulmonary complications**

Despite a large number of candidate definitions, the group was unable to reach a consensus on the best definition of postoperative pulmonary complications. Many definitions used component definitions, which differed widely in severity and underlying biological mechanism (e.g. atelectasis and acute respiratory distress). After a discussion, and having sought advice from the StEP steering committee, we have
recommended a new definition which allows lower severity pulmonary events to be captured as part of the overall clinical outcome (Box 1).

**Pneumonia**

Only the US Centers for Disease Control definition was recommended.\(^{37}\) Whilst there are numerous other well-written definitions, there seemed little value in departing from such a widely used international standard (Box 2).

**Respiratory failure**

The group recommended two definitions covering overlapping patient scenarios. The Berlin definition of Acute Respiratory Distress Syndrome was recommended, again because this is a widely used international standard, which has already been carefully developed in a consensus process. However, as many important episodes of postoperative respiratory failure are not severe enough to meet this definition, the group also recommended an adapted version of a definition reported by

---

**Table 3 Definitions of respiratory failure outcome measures.** *Chest radiograph or computed tomography scan. **If altitude is higher than 1000 m, a correction factor should be calculated [PaO$_2$-FiO$_2$ x (barometric pressure/101 kPa)]. ***This may be delivered non-invasively in the mild Acute Respiratory Distress Syndrome group**

<table>
<thead>
<tr>
<th>Lead author</th>
<th>Outcome measure</th>
<th>Definition</th>
<th>Round 1</th>
<th>Round 2</th>
<th>Round 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perkins and colleagues(^{51})</td>
<td>Acute lung injury</td>
<td>American-European Consensus Conference definition: acute onset of bilateral infiltrates on the chest radiograph and hypoxaemia (PaO$_2$/FiO$_2$ ratio of &lt;300) in the absence of clinical evidence of left atrial hypertension</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Canadian Orthopedic Trauma(^{62})</td>
<td>Acute Respiratory Distress Syndrome</td>
<td>1994 American-European consensus definition: (i) acute onset, (ii) bilateral chest infiltrate, (iii) pulmonary artery occlusion pressure of 18 mm Hg or less and no evidence of left atrial hypertension, (iv) impaired oxygenation regardless of the level of PEEP, and (v) a PaO$_2$/FiO$_2$ ratio of &lt;200.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>ARDS Definition Task Force(^{63})</td>
<td>Acute Respiratory Distress Syndrome</td>
<td>The Berlin definition of Respiratory Distress Syndrome: Timing. Within 1 week of a known clinical insult or new or worsening respiratory symptoms and Chest imaging. Bilateral opacities not fully explained by effusions, lobar/lung collapse or nodules and Origin of oedema. Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (e.g. echocardiography) to exclude hydrostatic oedema</td>
<td>Green</td>
<td>Median score 8</td>
<td>Median score 7</td>
</tr>
<tr>
<td>Camp and colleagues(^{64})</td>
<td>Early extubation</td>
<td>Removal of breathing tubes after arrival to cardiovascular intensive care.</td>
<td>Red</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Squadrone and colleagues(^{65})</td>
<td>Tracheal intubation</td>
<td>Intubation was performed when patients presented with one of: severe hypoxemia (arterial oxygen saturation &lt;89% despite maximal FiO$_2$; respiratory acidosis (arterial pH &lt;7.30 with carbon dioxide tension &gt;50 mm Hg); signs of patient distress with accessory muscle recruitment and paradoxical abdominal or thoracic motion; hemodynamic instability (80–90 mm Hg increase or a 30–40 mm Hg decrease in systolic blood pressure relative to the baseline value or need for inotropic drugs for at least 2 h to maintain systolic blood pressure higher than 85 mm Hg or electrocardiogram evidence of ischemia or significant ventricular arrhythmias); need for sedation for major agitation; decreased alertness defined as a Glasgow Coma Score &lt;9; or cardiac arrest.</td>
<td>Amber</td>
<td>Median score 5</td>
<td>Median score 5</td>
</tr>
<tr>
<td>Fernandez-Perez and colleagues(^{21})</td>
<td>Respiratory failure</td>
<td>Need for mechanical ventilation for &gt;48 h after operation or need for re-institution of mechanical or non-invasive ventilation after extubation</td>
<td>Amber</td>
<td>Median score 6</td>
<td>Median score 5</td>
</tr>
</tbody>
</table>

---

\(^{21}\) This may be delivered non-invasively in the mild Acute Respiratory Distress Syndrome group.
Fernandez-Perez and colleagues,\textsuperscript{21} which describes re-institution of mechanical or non-invasive ventilation after extubation (Box 3).

**Discussion**

We have summarised and evaluated a range of definitions used to describe pulmonary outcomes in perioperative medicine research. Many definitions were imprecise, or difficult to apply consistently in large patient populations because of the requirement from resource intensive diagnostic tests (e.g. bronchoscopy). The composite outcome of postoperative pulmonary complications was widely used, but the group was concerned about the lack of equivalence of component outcomes and the differing biological mechanisms, which may cause these. We therefore propose a new definition for this outcome. Importantly, this new definition includes a measure of severity which we hope will significantly reduce the subjectivity in evaluating pulmonary outcomes, and ensure a more valid comparison between studies. The group also

**Box 1**

**Recommended definition of postoperative pulmonary complications.**

**Postoperative pulmonary complications**

**Mechanism**

Composite of respiratory diagnoses that share common pathophysiological mechanisms including pulmonary collapse and airway contamination:

- (i) atelectasis detected on computed tomography or chest radiograph,
- (ii) pneumonia using US Centers for Disease Control criteria,
- (iii) Acute Respiratory Distress Syndrome using Berlin consensus definition,
- (iv) pulmonary aspiration (clear clinical history AND radiological evidence).

**Severity**

None: planned use of supplemental oxygen or mechanical respiratory support as part of routine care, but not in response to a complication or deteriorating physiology.

Therapies which are purely preventative or prophylactic for example high flow nasal oxygen or continuous positive airways pressure (CPAP) should be recorded as none

Mild: therapeutic supplemental oxygen $>0.6$ FiO\textsubscript{2}

Moderate: therapeutic supplemental oxygen $>0.6$ FiO\textsubscript{2}, requirement for high-flow nasal oxygen, or both

Severe: unplanned non-invasive mechanical ventilation, CPAP, or invasive mechanical ventilation requiring tracheal intubation

**Exclusions**

Other diagnoses that do not share a common biological mechanism are best evaluated separately and only when clearly relevant to the treatment under investigation:

- (i) pulmonary embolism,
- (ii) pleural effusion,
- (iii) cardiogenic pulmonary oedema,
- (iv) pneumothorax,
- (v) bronchospasm.

**Box 2**

**Recommended definition of postoperative pneumonia.**

**US Centers for Disease Control definition of pneumonia**

Two or more serial chest radiographs with at least one of the following (one radiograph is sufficient for patients with no underlying pulmonary or cardiac disease):

- (i) New or progressive and persistent infiltrates, (ii) consolidation, (iii) cavitation; AND at least one of the following:
  - (a) fever ($>38^\circ$C) with no other recognised cause,
  - (b) leucopaenia (white cell count $<4\times10^{9}$ litre$^{-1}$) or leucocytosis (white cell count $>12\times10^{9}$ litre$^{-1}$),
  - (c) for adults $>70$ yr old, altered mental status with no other recognised cause;

AND at least two of the following:

- (a) new onset of purulent sputum or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements,
- (b) new onset or worsening cough, or dyspnoea, or tachypnoea,
- (c) rales or bronchial breath sounds,
- (d) worsening gas exchange (hypoxaemia, increased oxygen requirement, increased ventilator demand).

**Box 3**

**Recommended definition of postoperative respiratory failure.**

**Berlin definition of Respiratory Distress Syndrome**

Timing: within 1 week of a known clinical insult or new or worsening respiratory symptoms AND...

Chest imaging: bilateral opacities not fully explained by effusions, lobar/lung collapse or nodules AND...

Origin of oedema: respiratory failure not fully explained by cardiac failure or fluid overload (requires objective assessment, e.g. echocardiography, to exclude hydrostatic oedema), AND...

Oxygenation: mild PaO\textsubscript{2}:FiO\textsubscript{2} between 26.7 and 40.0 kPa (200–300 mm Hg) with PEEP or CPAP $>5$ cm H\textsubscript{2}O; moderate PaO\textsubscript{2}:FiO\textsubscript{2} between 13.3 and 26.6 kPa (100–200 mm Hg) with PEEP $>5$ cm H\textsubscript{2}O; severe PaO\textsubscript{2}:FiO\textsubscript{2} $\leq13.3$ kPa (100 mm Hg) with PEEP $\geq5$ cm H\textsubscript{2}O.

**Mechanical ventilation**

The need for need for tracheal re-intubation and mechanical ventilation after extubation, and within 30 days after surgery OR mechanical ventilation for more than 24 h after surgery. The inclusion of non-invasive ventilation may be considered on a study by study basis.
In some cases, we did not identify existing research that utilised outcomes that would be considered important. An example is pulmonary thromboembolism, which can only be reliably detected through screening of all participating patients in a given trial. Some outcomes may be more appropriate for use in smaller studies or early phase trials (e.g. clinical pulmonary infection score). As previously noted, the physiological changes that follow surgery and anaesthesia, including the systemic inflammatory response, may result in partial compliance with the criteria for a number of outcome measures, in particular atelectasis. We note that reports relating to perioperative medicine are not easily identified through a literature search because there is no standard approach to the use of Medical Subject Headings (MeSH) terms by authors of perioperative medicine research articles. There is an argument for creating a new MeSH heading of ‘perioperative medicine’ to ensure that trials in this field are more easily identified.

The strengths of this project include a detailed and extensive systematic literature search followed by a robust three stage Delphi process including a core group of experts in postoperative pulmonary complications and the wider StEP group, which includes many of the leading international experts in perioperative care research. However, this work is limited by the large number of alternative definitions which have been used in previous research. In particular, we identified a large number of composite outcomes for postoperative pulmonary complications which included a diverse range of adverse events which differed widely in frequency, severity, and biological mechanism. As a result, the group was unable to make a strong recommendation for this important outcome, and instead we have recommended a new definition which we believe is less prone to methodological bias.

Conclusions

We have summarised and evaluated a wide range of pulmonary outcome measures in perioperative medicine research, most of which were poorly defined. Our four recommended outcome measures include a new definition of postoperative pulmonary complications, incorporating an assessment of severity. Together, these definitions will meet the needs of most clinical effectiveness trials of treatments to improve postoperative pulmonary outcomes, although not every definition will be relevant to every trial. This work represents part of an international initiative to improve the definition and use of outcome measures in clinical effectiveness trials in perioperative medicine. These projects include the recent work by the European Society of Anaesthesiology and European Society of Intensive Care Medicine joint taskforce on perioperative outcome measures, and the Core Outcome Measures in Perioperative and Anaesthetic Care (COMPAC) project which is part of the Core Outcome Measures in Effectiveness Trials (COMET) initiative.

Authors’ contributions

Contributed to protocol design, data acquisition, analysis, and preparation of the manuscript: all authors

Declaration of interest

R.M.P. holds research grants, and has given lectures, performed consultancy work, or both, for Nestle Health Sciences, B.Braun, Medtronic, Glaxo Smithkline, Intersurgical, and Edwards Lifesciences, and is a member of the associate editorial board of the British Journal of Anaesthesia. M.G.A. has given lectures, performed consultancy, or both, for Drägerwerk AG, Lübeck, Germany, and Ventinova Ltd, Eindhoven, The Netherlands. M.G. is an elected council member of the Royal College of Anaesthetists. T.G. is a member of the Editorial Board of Anesthesia and Analgesia. E.F. reported receiving consulting fees from Edwards Lifesciences and Dräger; lecture fees from Dräger, GE Healthcare, Edwards Lifesciences, Fisher and Paykel Healthcare, Fresenius Kabi, and Getinge. J.C. is Associate Editor of Anesthesiology. M.G. is the National Specialty Lead for Anaesthesia, Perioperative Medicine and Pain within the UK National Institute of Health Research Clinical Research Network, an elected council member of the Royal College of Anaesthetists and serves on the board of Oxygen Control Systems Ltd, the Evidence Based Perioperative Medicine (EBPOM) social enterprise and the medical advisory board of Sphere Medical Ltd. M.G. has received honoraria for speaking, travel expenses, or both, from Edwards Lifesciences, Fresenius-Kabi, BOC Medical (Linde Group), Ely-Lilly Critical Care, and Cortex GmBH. M.G. is Executive Chair of the Xtreme-Everest Oxygen Research Consortium and joint Editor-in-Chief of Perioperative Medicine. M.M. is a paid consultant for Edwards Lifesciences, Deltex and Baxter; his chair at UCL is sponsored by Smiths Medical; Director Evidence Based Perioperative Medicine (EBPOM) Community Interest Company, director of Medinspire Ltd, Clinical Hydration Solutions, Clinical Fabric Solutions Ltd, Oxygen Control Systems Ltd, and a share-holder and scientific advisor for Medical Defense Technologies LLC. M.M. sits on the editorial boards of the British Journal of Anaesthesia, Critical Care and is Editor-in-Chief of Perioperative Medicine. All other authors declare no conflicts of interest.

Funding

The Standardized Endpoints for Perioperative Medicine (StEP) Collaborative is supported by an unrestricted grant from the British Journal of Anaesthesia. T.E.F.A. was supported by a Medical Research Council and British Journal of Anaesthesia Clinical Research Training Fellowship. R.M.P. is a National Institute for Health Research (UK) Professor.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.bja.2018.02.007.

References

11. Ireland CJ, Chapman TM, Mathew SF, Herbison GP, Zacharias M. Continuous positive airway pressure (CPAP) during the postoperative period for prevention of postoperative morbidity and mortality following major abdominal surgery. Cochrane Database Syst Rev 2014; 8, CD008930-CD
14. Tovey D. The impact of cochrane reviews. Cochrane Data Base Syst Rev 2011; 111. ED000007
35. Hemmes SNT, Gama de Abreu M, Pelosi P, Schultz MJ, the PNIifCTNo, European Society of A. High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial. Lancet 2014; 384: 495–503
36. Hodari A, Tsiouris A, Eichenhorn M, Horst M, Rubinfeld I. Exploring National Surgical Quality Improvement Program respiratory comorbidities: developing a predictive understanding of postoperative respiratory occurrences,
59. Nicolosi LN, del Carmen Rubio M, Martinez CD, Gonzalez NN, Cruz ME. Effect of oral hygiene and 0.12% chlorhexidine gluconate oral rinse in preventing ventilator-associated pneumonia after cardiovascular surgery. Respir Care 2014; 59: 504–9

Handling editor: H.C. Hemmings Jr